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Abstract
Vitamin K antagonists (VKA) are used in human medicine as well as for the manage‐
ment  of  rodent  populations.  In  both  cases,  we  have  to  deal  with  inter-individual
resistances.  Many mechanisms of resistances are common in humans and rodents.
Moreover,  with  the  large  use  of  vitamin  K  antagonist  rodenticides,  the  resistant
phenotype  is  overrepresented  in  some  rodent  populations.  Consequently,  some
resistance mechanisms with a low prevalence in the human population have a higher
prevalence in rodent population; thus, they can be more studied in rodents. The aim of
this chapter is to cross knowledge coming from human medicine and rodent research
in order to better understand each resistance mechanism. After an overview of the
essential knowledge for the understanding of the VKA action, this chapter presents the
different  methods  of  VKA  resistance  studying  and  then  it  assesses  the  current
knowledge on VKA resistance in humans and rodents.
Keywords: vitamin K antagonists, warfarin, comparative biology, pharmacogenomics
1. Introduction
Vitamin K antagonists  (VKA) are  inhibitors  of  the regeneration cycle  of  vitamin K.  The
diminution of the available and usable vitamin K in the body induced by VKA leads indirectly
to a hypocoagulable status of the blood. The use of VKA in humans and rodents pursues this
status. Nevertheless, the final aim is different for each. In the human case, VKA anticoagu‐
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
lants are used to prevent venous and arterial thrombotic event. In spite of the increasing use
of  new oral  anticoagulants,  VKA and,  more precisely,  warfarin are  the most  commonly
prescribed  anticoagulants  [1].  Considering  rodents,  VKA  are  used  in  pest  population
management. In this case, death resulting from hemorrhages is pursued. VKA are currently
the most used and one of the best rodenticides for two reasons. First, the delay between VKA
administration and death is of several days, which avoids association between bait and death
by the other rodents. Second, conversely to other rodenticides, VKA have an antidote: the
vitamin K, which increases their safety for the human population and nontarget species.
In humans, VKA anticoagulants have a narrow therapeutic range [2]. Under- and overdoses
can have serious consequences by the lack of efficacy or adverse event. Warfarin has been
ranked number 9 among primary suspect drugs having serious outcomes in the United States
during the beginning of the 2000’s decade [3]. Indeed, the VKA dose has to be modulated,
reflecting the genotype of patients more than other common drugs. Thus, it is necessary to
identify and characterize each gene and mutation which may influence the VKA dose. In this
task, the VKA research on pest management can be helpful. Indeed, management of rodent
population has to deal with VKA resistances as well as in human medicine. Many mechanisms
of resistances are common in humans and rodents. Moreover, with the large use of vitamin K
antagonist rodenticides, the resistant phenotype is over-represented in some rodent popula‐
tions. Consequently, some resistance mechanisms with a low prevalence in the human
population have a higher prevalence in rodent population; thus, they can be more studied in
rodents.
After a rapid presentation of the basis of vitamin K and VKA mechanisms, this chapter presents
the different methods to assess VKA resistance mechanisms. Then, an assessment of the VKA-
resistant pathways described in humans and in different rodent species is performed.
2. Basis of vitamin K metabolism
2.1. Vitamin K
The name “vitamin K” gathers a great number of molecules. All vitamin K are based on a
naphthoquinone core and are sorted in three classes, numbered from 1 to 3. The substitution
on the carbon 3 of the core determinates the class of the vitamin K. Vitamin K1 is composed
of only one molecule, the phylloquinone, where the carbon 3 is substituted by a phytyl moiety.
It was the first vitamin K described in 1935 by Dam [4], and chemically identified and synthe‐
sized by Doisy [5]. Vitamin K2 regroups the menaquinones. The substitute is a chain of prenyl,
and the number of prenyls is indicated in the name. For example, the menaquinone 4 side chain
is composed of 4 prenyl. Finally, vitamin K3 or menadione is only constituted by the naph‐
thoquinone core (Figure 1).
Phylloquinone is synthesized by plants [6]. Menaquinones are synthesized from phylloqui‐
none. The number of prenyls of the synthesized menaquinone depends on the bacteria, fungi,
and animals which synthesize them. Mammals are only able to synthesize menaquinone 4 with
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the help of the UBIAD1 gene [7, 8]. Consequently, other menaquinone forms come mainly from
fermented alimentation or gut microbial synthesis [9, 10].
Figure 1. Examples of vitamin K: (A) menadione; (B) phylloquinone; (C) menaquinone 4; (D) menaquinone 7.
As many other fat-soluble vitamins, vitamin K’s absorption increases with fatty intake [11].
The absorption of vitamin K occurs in the gut, nevertheless its mechanism has been unclear
during many years [12]. Recently, a study suggested that the cholesterol transporter, the
Niemann-Pick C1-like 1 protein, would be responsible for the vitamin K’s absorption [13].
2.2. Vitamin K roles
The name of the vitamin K comes from the German word “koagulation.” Indeed, when vitamin
K was discovered, its deficiency involved bleeding [4]. Nevertheless, it is only in the 1970s that
we began to understand the vitamin K’s mechanism of action. Vitamin K is a cofactor of a post-
transcriptional gamma-carboxylation which activates vitamin-K dependent proteins (VKDP)
[14]. Four clotting factors of the coagulation cascade are the VKDPs, factors II, VII, IX, and X,
which explain the bleeding issues observed in case of deficiency. Proteins C, S, and Z are also
VKDPs involved in coagulation, but they have an antithrombotic effect. Nevertheless, the main
effect of VKA is anticoagulation, even though the rapid decrease of these antithrombotic
molecules can lead to a transient hypercoagulable state at the beginning or at the end of
treatment with possible adverse events [15, 16].
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The second great role of vitamin K is bone regulation with two VKDPs: osteocalcin and matrix
GLA protein [17, 18]. This last protein is also involved in the protection against tissue calcifi‐
cation [19]. Vitamin K is involved in many other biological functions which are reviewed in
Refs. [20, 21].
2.3. Vitamin K regeneration cycle
2.3.1. Vitamin K cycle
In spite of the low vitamin K level in food, vitamin K deficiency is rare [22]. Indeed, vitamin
K is recycled by cells. The cycle is composed of two great steps: the use of vitamin K hydro‐
quinone by the GGCX enzyme to activate VKDPs and the regeneration of the vitamin K
hydroquinone from the epoxide form by VKORC1 (Figure 2).
Figure 2. Vitamin K regeneration cycle.
In order to chelate calcium and to be active, the glutamate residues (Glu) of VKDPs have to be
carboxylated to carboxyglutamic acid (Gla). This reaction is mediated by gamma-glutamyl
carboxylase (GGCX). GGCX recognizes the VKDPs with the the help of their propeptide [23,
24]. Then, GGCX removes the gamma-hydrogen of Glu residues and adds CO2; the oxidation
of vitamin K hydroquinone (KH2) to vitamin K epoxide (K > 0) provides the required energy
[25]. This reaction is performed in the endoplasmic reticulum [26].
2.3.2. VKORC1 structure
The VKORC1 gene was located in 1969 on the chromosome 1 of rat by discovering a link
between the coat color heritage and the resistance to warfarin [27]. Then it was located on the
chromosome 7 of mice in 1976 [28] and on the human chromosome 16 in 2002 [29]. The first
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characterization of the VKORC1 activity was performed in 1974; nevertheless, at this time the
responsible protein of this activity was unknown [30]. The identification of the VKORC1 coding
gene has only been performed in 2004 by two teams: one used short interference RNA
functional screening [31] and the other used interspecies genetic linkage analysis [32]. Once
identified and sequenced, the VKORC1’s structure and function study begun.
A complete review of the current knowledge on the VKORC1 structure has been recently done
[33]. VKORC1 is a membrane protein of the endoplasmic reticulum. The activity of VKORC1
seems to be due to CXXC patterns. VKORC1 presents two CXXC patterns, with cysteines
positioned at Cys43, Cys51, Cys132, and Cys135 in human VKORC1. These cysteines are
widely conserved through species, which might indicate that they have a key role in VKOR
activity [34]. Cys132 and Cys135 are located in a transmembrane domain. They seem to be
essential for the VKORC1 activity and might lead the nucleophilic attack supposed by a
biochemical model of the VKOR reaction [34, 35]. Mutation of one of them to serine abolishes
the enzymatic VKOR activity [36]. To reduce vitamin K, VKORC1 needs to be itself reduced
by aphysiological partner. This partner and its mechanism of action are currently unknown.
Schulman et al. proposed that the partner might reduce the loop cysteines (Cys43 and Cys51).
Then the loop cysteines would transfer the reducing power to Cys132 and Cys135 of the active
site [37]. However, other studies have reported that the mutation of one of these cysteines to
serine has no consequence on the VKORC1 activity [38–40]. Moreover, the conformation of
VKORC1 is still under debate between a topology with three transmembrane domains or four
[41]. This last point is determining for the comprehension of the possible role of the loop
cysteines. Indeed, they are either in the cytosol for the three transmembrane model or in the
endoplasmic reticulum’s lumen for the other model.
VKORC1 presents a strong homology between rodents and humans, allowing to compare the
mutation between them. Mammals and bacterial VKORs are homologs, but their conformation
and reaction seem different [42].
Mammals have another enzyme able to reduce the vitamin K epoxide, the VKORC1L1. It is
mainly expressed in the extrahepatic tissues [43–45] and has a great similarity with VKORC1
[46]. Its inhibition by VKA is lower than its homolog [43]. Nevertheless, due to its low hepatic
expression, its influence on the anticoagulant resistance is negligible. However, it might
explain that the other vitamin K functions are not significantly impacted by VKA treatments.
2.4. Vitamin K antagonists
First VKA has been discovered in 1941 and then isolated in spoiled sweet clover by Hueber
and Link [47]. Sweet clover (Melilotus officinalis) contains coumarin. In a poorly preserved silage
or hay, this coumarin can be changed to dicoumarol by Penicillium species commonly present
in soil [48, 49]. The dicoumarol contained in spoiled forage causes a hemorrhagic condition
called sweet clover disease. Some years after this discovery, Coumadin, a synthetic VKA also
called warfarin, was synthesized [50]. This last molecule is still the most commonly prescribed
anticoagulant. Concerning rodents, many new VKA have been developed to reply to resistance
emergence.
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Three VKA families are used: the 4-hydroxycoumarin derivatives, the 4-hydroxy-thiocoumar‐
in derivatives, and the indane-1,3-dione derivatives (Figure 3). All derivatives are used against
rodents. Conversely, in human medicine, only the 4-hydroxycoumarin derivatives (for
instance, warfarin) and the indane-1,3-dione derivatives (for instance, fluindione) are used.
Moreover, in order to deal with rodent resistances, second generation of 4-hydroxycoumarin
derivatives and of 4-hydroxy-thiocoumarin derivatives have been designed with complex
radicals (Figure 3C and D).
Figure 3. Examples of some VKA: (A) warfarin; (B) fluindione; (C) difethialone; (D) brodifacoum.
2.4.1. Mechanism of VKA action
Vitamin K antagonists stop the vitamin K recycling by performing noncompetitive inhibition
of the VKORC1 enzyme [51, 52]. Nevertheless, the binding of VKA with VKORC1 enzyme is
still a gray area. The reversibility of the binding is presently unknown [52–54], as well as the
binding site. First, the binding site has been located at the level of the TYA motif (residues 138–
140 in human VKORC1) close to the CXXC active site. Indeed, the mutation of the 139 tyrosine
of this motif is associated with warfarin resistance in humans and rodents [55, 56], and by
analogy the dicoumarol’s binding site on NQO1 is also a TYA motif [57]. However, these
mutations are moderately susceptible to second generation VKAs in rats [55, 58], which can
suggest that other amino acids might be involved in this binding. Recently, Czogalla et al. have
proposed a model involving three binding interfaces between warfarin and human VKORC1
[59].
2.4.2. VKA elimination pathway
The VKA treatments are established on the long term. Consequently, their elimination is a key
factor which determines their liver concentration and finally their efficiency. The elimination
pathway seems to depend on the molecule and on its enantiomeric form. Indeed, enantiomers
of warfarin are eliminated differently. The (S)-enantiomer is metabolized exclusively by the
Anticoagulation Therapy24
hepatic cytochrome P450 isoform 2C9 (CYP2C9), while (R)-enantiomer is metabolized by
isoforms CYP1A2, CYP2C19, CYP3A, and hepatic ketoreductase [60, 61]. Although the (R)-
enantiomer has a longer half-life, it is less efficient, and the modulation of its elimination has
no significant impact on the coagulation [62–64]. However, the activity of CYP2C9 is critical
in the determination of the warfarin dose. Indeed, CYP2C9 activity is influenced by many drug
interactions [65–68], and polymorphism of CYP2C9 can also modulate the sensitivity to
warfarin.
3. Assess the resistances
Since the discovery of rats that are resistant to warfarin in 1960 by Boyle [69], the assessment
and the study of resistance mechanisms have become a key issue for the rodent population
management and in human medicine. Many methods have been developed to study these
resistance mechanisms. Their purpose is to isolate the possible origins of the resistance in a
standardized model and to evaluate if the induced resistance factor is of the same order as that
one observed in vivo. The resistance factor is the factor by which the dose or concentration of
VKA required for a susceptible population must be multiplied to achieve the same effect within
a resistant population. We present below the main methods, and for each we pinpoint its
advantages and limits.
3.1. In vivo animal studies
In vivo studies were commonly used in rodent VKA research in order to evaluate the efficiency
of an anticoagulant or the consequences of VKORC1 mutations. The first resistance case in
rodents was assessed by Boyle. He fed suspected resistant with containing VKA food and
control rats during 5 days. Then, the death rate between the two groups was compared [69].
This kind of survival challenge is efficient to qualify a resistance state and remains the gold
standard to test commercial rodenticides. Nevertheless, these tests are long and have many
shortcomings concerning animal welfare and the repeatability. Moreover, it is difficult with
this test to compare two VKAs and to assess the dose–response law.
Later, new methods based on blood clotting test have been developed [70–72]. They were
standardized by the Rodenticide Resistance Action Committee in order to obtain a discrimi‐
nating dose for each VKA [73]. These doses of anticoagulants, called effective doses 50 (ED50),
were determined to quantify the susceptibility of rats to anticoagulants. ED50 is the dose
leading to 50% of animals tested with a fivefold increase of the international normalized ratio
24 h after the administration of anticoagulants. This technique is more precise and rapid.
Nevertheless, this method gives few information on the mechanism of resistance.
The origins of resistances in wild strain can be multifactorial. For example, they can involve
VKORC1-linked resistance and cytochrome-linked resistance. It is possible to refine in vivo
methods by introgressing the studied wild mutation in laboratory stain. With this method, it
is possible to isolate the resistant mutation in a susceptible genetic background [55].
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If the animal in vivo studies are still the gold standard to the understanding of the complex
effect of VKAs and of resistant mutations, they are expensive and laborious in the preparation
and care of the strain and in the realization of experiments. Moreover, it may be interesting to
study more precisely each mechanism by in vitro methods [74].
3.2. In vitro enzymatic study
The VKOR activity can be reproduced in vitro. These methods are based on the kinetics of
vitamin K quinone production by an enzyme system from vitamin K > O. To perform this
reaction, the substrate (vitamin K > O) is beforehand synthesized according to the method
described by Tishler et al. [75]. The evaluated enzyme can come from animal tissues or
heterologous expression culture (cell, bacteria, yeast, etc.). Finally, dithiothreitol (DTT) is
commonly used to transfer the reduction power to the enzyme. The studied VKOR-specific
activity and the Michaelis constant are calculated [76]. It is also possible to add VKA to study
its inhibition efficiency. In this case, an inhibition constant can be obtained for each couple of
enzymatic system and VKA. Methods to perform these experiments are described in Refs. [43,
58, 76].
This simple experiment pattern allows us to assess the efficiency of large origins of enzymatic
system. As the VKOR proteins are located in the membrane of the endoplasmic reticulum, they
are present in the microsomal fraction of tissues. The commonly used microsomal preparation
methods are described in Ref. [76]. Microsomes are prepared from other cell components by
differential centrifugation. Microsomal enzymatic activity evaluates the enzymatic efficiency
of whole microsomal VKOR activity and not only of the VKORC1 enzyme activity. Indeed,
Hammed et al. have pinpointed that a modeling with two enzymes (VKORC1L1 and VKORC1)
is necessary to explain the inhibition of the testis microsomal activity by warfarin [43].
Moreover, as for in vivo experiment, the strains with interesting mutations have to be selected
and preserved.
To isolate the activity of one enzyme or to perform enzymatic activity with human-like enzyme
or mutated enzyme, it is possible to perform a heterologous expression in yeast (Pichia
pastoris) of VKOR enzymes and then extract the yeast’s microsomes. The method is described
in Ref. [58]. Yeast has neither endogenous VKORC1 nor VKORC1L1. Thus, this method allows
the study of the influence of VKORC1 and/or VKORC1L1 mutation on their respective specific
activities and VKA resistance without interaction. The yeast model has been validated for some
mutations as Y139F for which the resistance rate of rat’s liver microsomes is the same as that
of yeast microsomes. Moreover, it is also possible to test some hypothetic mutations. The yeast
expression method is more focused on the enzyme activity than tissue microsomes and opens
many experimental opportunities. However, the studied activity is still the microsome activity.
With the previous methods, enzymes are in their microsomal environment. In order to study
more precisely VKORC1-linked resistances, it would be interesting to purify VKORC1.
The purification of VKORC1 was for many years a big business [77, 78]. Indeed, this enzyme
loses its activity during the solubilization. It was only in 2006 than Chu et al. have purified the
recombinant human VKORC1 produced from a baculovirus in insect cells which was still
active after purification [79]. In this experiment, microsomes were washed from non-VKORC1
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proteins. The artificial membrane inclusion of VKORC1 after heterologous expression in
Escherichia coli, its extraction, and its purification have recently been described [80]. Briefly, the
hVKORC1 gene has been expressed in E. coli BL21(DE3) in a KSI–hVKORC1–His6 construct
[81]. The ketosteroid isomerase (KSI) part promotes the expression of the protein in insoluble
inclusion bodies. KSI part was linked with hVKORC1 by a formic acid cleavage site. Finally,
the construct was hexahistidine-tagged. After the expression, proteins were preserved under
denaturing conditions and purified with a HisTrap Ni-NTA column. Then the KSI part is
removed with formic acid. The refolding of hVKORC1 was performed with pulsated renatu‐
ration and “artificial chaperone.” Then the proteins were incorporated in a lipid layer to form
a liposome. Jaeneke reported that the obtained hVKORC1 liposome had only 10% of the
specific activity of the enzyme obtained with HEK293 cell [80]. These new purification methods
are not currently used in the resistance study and need improvement. Nevertheless, they open
the way for a better understanding of the VKORC1 topology and the influence of mutations
on VKOR activity.
The enzymology studies are the basis of our current understanding of VKORC1 mutations and
interaction with VKA. It is currently the technique with the best reproducibility and more
reliability. Nevertheless, some issues are still pending with these methods. The major issue
comes from the DTT which gives the reducing power to VKORC1 in experiments. DTT is a
powerful reductor which might bypass some dysfunctional mechanisms of mutated enzyme
by directly activating the active site [37]. Moreover, high concentration of DTT (>1 mM) add a
background level. To limit it, Krettler et al. proposed the use of tris(3-hydroxypropyl)phos‐
phine instead of DTT [82]. Nevertheless, there is not enough knowledge currently on this new
methods and its VKORC1 interaction to change the method. Moreover, tris(3-hydroxyprop‐
yl)phosphine is less efficient in VKORC1 enzyme reduction than DTT at usual concentration.
Another issue might be that these methods study only the impact of VKA and resistant
VKORC1 enzyme on the vitamin K regeneration cycle and not on the vitamin K-dependent
protein gamma carboxylation. The required lipid environment and detergents are different for
the activity between GGCX and VKORC1. Thus, it is currently difficult to study the interaction
between both enzymes in an in vitro enzymatic assay [83]. These discrepancies imply that
enzymology results have to be analyzed in view of the in vivo results.
3.3. In vitro cell study
In order to evaluate the complete reaction from vitamin K reduction to gamma-carboxylation
and to solve some enzymatic study issues, the functional study of the vitamin K cycle in
mammalian cells has been recently developed by Tie et al. [83], which was then adapted by
other teams [84, 85]. In these studies, the production of a complete carboxylated protein by cell
culture was assessed. The cells were HEK 293 cells transfected with the studied VKORC1 gene
and a VKDP. Then, cells were cultured in an environment containing vitamin K epoxide and
the studied VKA. All methods have followed the gamma-carboxylation of factor IX gla domain
by its monoclonal antibodies recognition [86] or by measuring its activity (only for complete
factor IX). Three different vitamin K-dependent proteins have been used: the simple factor IX
protein (FIX) [59, 84, 87]; the chimeric protein FactIXGLA, which was protein C with its gla
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domain replaced by the factor IX gla domain [40, 83]; the chimeric protein FIXgla-PRGP2, as
previously the gla domain of the proline-rich gla protein was replaced by FIXgla domain [85].
Concerning the method using FIX [84, 87], the gamma-carboxylation was assessed by meas‐
uring the clotting activity of the concentrated culture medium mixed with factor IX-depleted
plasma. For the FIXgla-PC method [40, 83], quantification is performed on the culture medium
by an enzyme-linked immunosorbent assay (ELISA) with anti-FIXgla domain antibodies as
coating antibodies. Although Jamil also used a chimeric protein transformed with a FIXgla
domain for its quantification, in this case, it was the membrane protein, the proline-rich Gla
protein 2, which was used. With this modification, carboxylated protein gla domains were
presented at the surface of the cell, then recognized by monoclonal antibody conjugated to
allophycocyanin and quantified by flow cytometer [85].
This new method is not standardized yet, and there is still a gray area in the interpretation of
the obtained results. Indeed, some discrepancies exist between enzymatic assay and cell assay
results [84, 88] and even between cell assay results [40, 59]. The origin of these discrepancies
might be the interference of the cell’s endogenous enzymes, in particular VKORC1L1, which
is naturally more resistant than the wild VKORC1 enzyme [43]. In this way, standard cell assays
have showed that all tested mutations were resistant [59, 84]. Tie et al. have dealt with this by
knocking out endogenous VKORC1 and VKORC1L1 genes, using the transcription activator-
like effector nuclease technology [40]. Thus, Tie et al. have confirmed the interaction of the
endogenous enzyme in the cell assay, and they have showed that some mutations previously
classed as resistant by Czogalla et al. [59] are in fact not resistant [40].
The second issue for the interpretation of cell assay is the lack of knowledge and control on it.
This kind of assay is more complex than simple enzymatic activity; it involves many mecha‐
nisms that are currently uncontrolled or unknown: the level of the recombinant VKORC1
enzymes and the recombinant VKDP; the quantity and the efficiency of the physiological
partner of VKOR enzymes, which are still unknown; the level of the endogenous GGCX
protein; finally, the possible other mechanisms currently undescribed. All these elements
determine if the studied enzymes are not bypassed and if the vitamin K reduction is the limiting
reaction. These two conditions have to be fulfilled to validate completely the cell assay.
However, some studies have pinpointed that the limiting reaction might be the VKORC1
enzyme reduction by its physiological partner and not the vitamin K reduction [89–91].
Although cell assays are recent and still have a gray area in the interpretation of their results,
there is no doubt that they will become a key element of the study of VKA resistance mecha‐
nisms.
3.4. Pharmacogenomics study
The pharmacogenomics studies are the main source of in vivo information on the VKA
resistance in humans. These studies assess the correlation between some genetic parameters
and the warfarin dose, which allows to keep the patient’s INR in the target zone. Among these
parameters, the VKORC1 and the CYP2C9 polymorphisms are keys. But many other param‐
eters, which might influence the VKA susceptibility, are unknown and cannot be evaluated
by these studies. Pharmacogenomics studies assess the epidemiology of the mutations linked
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to resistance and can help in the determination of the treatment’s starting dose by taking in
account of patient’s genome. But, their contribution to the study of the resistance pathway is
limited to the confirmation or not of the results obtained with other methods.
4. Resistance pathways
4.1. VKOR-linked resistances
4.1.1. VKORC1 human genotypes
The pharmacogenomic studies and the reports of warfarin treatment failures have pinpointed
two kinds of polymorphisms linked to VKORC1 which influence the warfarin dose require‐
ments. The first is linked to the polymorphism in the noncoding region and the second is linked
to missense mutations.
The polymorphism in the noncoding region is the origin of the majority of VKA dose variations
[92–95]. Indeed, the noncoding region influences the transcription level of VKORC1 [94].
Nevertheless, these variations are minor, few milligrams of increase or decrease. So, it is not
really resistance to VKA, but rather a slight modulation of VKA sensibility.
Conversely, the VKORC1 coding mutations are rare, and some involve a real resistance to
VKA. They are characterized by a dose to stabilize the anticoagulation, which is higher than
the high-dose threshold defined by Watzka: phenprocoumon 3.0 mg/day, acenocoumarol 3.5
mg/day, warfarin (W) 7.1 mg/day, and fluindione 19.8 mg/day, for mean age patients [56].
Please note that the definition of warfarin resistance is not well-defined. Currently, there are
more than 27 mutations that have been described in patients with high requirements of VKA
dose. They are summarized in Table 1.
Mutation  Number of patients Molecule  Dose (mg /day)  Stable
anticoa-
gulation 
Ref. Confirmation of
resistance by
in vitro method†
A26P 1 W
F
20
100
No
No
[106] Yes [88]
A26T 1 W 6 No [56] No [88]
L27V 1 W
F
7
60
Yes
No
[107] No [88]
H28Q 1 P 10 yes [56] No [88]
V29L 2 W
P
14
26
?
Yes
[32, 56]
A34P 1 W 27 Yes [108]
D36Y 31 W
F
16.1 [3–36]*
45
~
No
[56, 96, 105,
106, 109
No [88]
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Mutation  Number of patients Molecule  Dose (mg /day)  Stable
anticoa-
gulation 
Ref. Confirmation of
resistance by
in vitro method†
A
P
7
7 [6.9–7.1]
No
Yes
–112]
D36G 1 W 20 Yes [56] No [88]
A41S 1 W 16 ? [94] No [88]
V45A 1 W 45 No [32] No [88]
S52L 1 P 9 No [113] Yes [40]
S52W 1 P 10 Yes [56] No [40]
V54L 2 W
F
A
21 [10–32]
60
8
~
No
No
[105, 106] Yes [88]
S56F 1 P 15 No [56] No [88]
R58G 1 W 34 ? [32] No [88]
W59R 3 A
P
9.3 [8–12]
9
No
No
[113, 114] Yes [40]
W59C 1 P 11 No [56] No [88]
W59L 1 P 15 No [56] Yes [40]
V66M 15 W
P
31.5 [20–42]**
9.5 [9–10]
Yes
~
[56, 103, 105,
106, 108]
No [40]
V66G 1 P 8 Yes [56] No [40]
H68Y 1 – – – [115] Yes [88]
G71A 1 P 6 No [56] No [40]
N77S 1 P 9 No [56] Yes [40]
N77Y 1 W 25 Yes [56] No [40]
I123N 1 P 21 No [56] Yes [88]
L128R 16 W
F
A
P
44
80
13
30
No
No
No
No
[32, 105,
106, 116]
Yes [40]
Y139H 1 P 9 No [56] Yes [88]
Adapted and completed with permission from Ref. [88].
* A case report, which includes a 2-year-old girl, is not included [117].
** A report of two cases was not used due to its imprecision on the doses [118].
† Results of the Oldenburg’s team are not reported [59, 84].
? no data are present on the stabilization of the anticoagulation in study.
~ only some patients have a stabilization of their anticoagulation.
Table 1. Genetic variations in the coding sequence of human VKORC1 in patients requiring high dose of a vitamin K
antagonist.
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Conversely, another mutation has been described by Rost in two Libyan families, the R98W
mutation. Homozygous patients with this mutation have a combined deficiency of vitamin-
K-dependent clotting factor type 2 which causes bleeding [32]. This deficiency can be treated
by a daily dose of vitamin K. Rost et al. have shown in enzymatic assays that R98W-muted
VKORC1, which was expressed in HEK cell, has a VKOR activity diminished of 90% [32].
Some mutations have a higher prevalence in some populations. Thus, the D36Y mutation is
relatively well represented in some African populations [96]. The Ethiopian population and
the Ashkenazi Jews population have a D36Y allele frequency of respectively 15% and 4% [97–
99], while this mutation is absent in South African or in Chinese populations [100, 101].
Concerning the V66M mutation, it has been described in African and African-descent popu‐
lations [102–104]. Finally, the L128R mutation has been described in different families [32, 105].
Nevertheless, the other reported mutations have been described only one time and sometimes
on patient with unstabilized anticoagulation. These elements reduce the possibilities to
determine a resistance factor for each. Moreover, the mutations have been often described as
fortuitous events of pharmacogenomics studies [94]. Finally, the interactions with other
mutations on cytochromes, GGCX, or noncoding part of VKORC1 genes can also modulate the
warfarin dose and enhance or reduce the resistance. Thus, the assessment of these mutations
only from case report entails a lot of bias.
In order to deal with the described bias, the in vitro results can be useful. The in vitro results
from enzymology [88] and cell assays [40] have been reported in Table 1. Nevertheless, all
mutations do not seem to be associated with resistance in in vitro assays. Only Oldenburg have
found that all the VKORC1 coding mutations were resistant with a cell method assay; his
results are not reported in the table [59, 84]. This discrepancy between assays might be due to
the VKORC1L1 gene as afore-explained in the description of the cell assays. Moreover,
enzymology assay pinpoints that some mutations drastically diminish the VKOR activity of
the enzyme [88], whereas cell assays do not [40]. The study of the paralog mutations in rodents
may help to understand the real impact of these mutations on the resistance.
4.1.2. VKORC1 rodent genotypes
Resistances have evolved differently in rodents according to their species. Indeed, the
anticoagulant pressure is exerted differently on each. These differences depend on the behavior
of the rodents, and more particularly the feeding behavior. Thus, some rodents feed prefer‐
entially on one food source (rat), while others feed on many sources (house mice). Thus, rats
eat a lot of poisoned grains, whereas mice eat few poisoned baits and dilute them with other
food sources.
Resistances have been largely described in house mice (Mus musculus) and in Norway rat
(Rattus norvegicus). VKORC1-linked resistances are due to missense mutations. They have been
detected whereupon rodenticide treatment fails. Due to the purpose of the VKA rodenticides,
their doses used for management of rodents are important. Consequently, only huge resis‐
tances have been pinpointed and then isolated by introgressing the concerned genes in
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laboratory strains. Thus, the noncoding mutations, which are involved in the modulation of
VKA dose in humans, have not been described in rodents.
Concerning the Norway rat, it has been the first target of the VKA rodenticides and the first
to develop resistances [69]. The first description occurred in Scotland, and rapidly the resist‐
ance spread all over Great Britain [119, 120]. Denmark has been the second country with
warfarin-resistant rats [121]. Entrapments have pinpointed that 24.2% of Denmark’s rats were
resistant in the 1960s [122]. Since then, resistances have been brought to light from all around
the world [123, 124].
Currently, 25 mutations have been described in Norway rats [125]. Nevertheless, only few
mutations are widely present and linked with important resistances. The five main mutations
in Europe are L120Q, L128Q, Y139C, Y139F, and Y139S [126]. These mutations have different
frequencies depending on the geographical areas. Thus, Y139C is the main mutation in
Germany and Denmark [126, 127], and Y139F in France [128]. Concerning Great Britain,
important discrepancies on the frequencies of mutations have been pinpointed between
counties [126, 129, 130]. The frequencies of rat mutations are disproportionate comparatively
to human coding mutation frequency. Thus, Y139F mutation is detected in 21% of the French
rats [128], but less than 1% of the world human population carries one coding mutation.
Moreover, in some areas, the prevalence of the resistant rats is of 100% [131].
Concerning the house mice, their mutations have been described in 1961 in many countries
[132]. Currently, more than 10 VKORC1 mutations have been described [133]. Moreover, 80%
of the trapped mice carried at least one VKORC1 mutation in a study in Germany, Switzerland,
and Azores [133]. Finally, some population of house mice have multiple mutations, Arg12Trp/
Ala26Ser/Ala48Thr/Arg61Leu, which involve VKA resistance [133]. This mutation may come
from an interspecific hybridization with Mus spretus. But, only little information is available
on Mus spretus’s resistance to VKA [133].
4.1.3. Overall approach of human and rodent mutations
The presence of VKORC1 mutations in humans with very low frequency (<1%) and the fast
emergence of resistance in rodents indicate that the mutations were present in rodents well
before the use of VKA as rodenticide. The large use of these molecules has selected the resistant
mutations of VKORC1 and increased their prevalence in rodent populations. Moreover, the
use of excessive dose of VKA has selected the mutations leading to the most severe resistance,
especially in Rattus norvegicus populations. Indeed, in Europe, while more than 20 mutations
were published, only three mutations seem now widely spread. As the roof rat population is
less exposed to VKA than brown rats, the prevalence of their VKORC1 mutations might be
close to human prevalence. The roof rat resistance linked to VKORC1 mutation has not been
widely explored. Recently, Goulois has characterized the Y25F mutation in roof rats [134].
Five amino acid positions of the VKORC1 enzyme carry a described mutation in both humans
and rodents. They are the positions A26, R58, W59, L128, and Y139. Nevertheless, only the
mutations A26T, R58G, and W59R are identical. These three mutations are not common in
humans, and the reported cases did not have a stable anticoagulation. The A26T mutation does
Anticoagulation Therapy32
not seem to enhance the resistance in the rat [125]. These results were obtained with rat
VKORC1 cell expression, and they agree with the results obtained with human VKORC1 [88].
Moreover, the frequency of this mutation is low in rats which might suggest that the resistance
linked to this mutation is insufficient to be selected by the VKA rodenticide pressure. Con‐
cerning the W59R mutation, it diminishes considerably the VKOR activity of the enzyme in
rats conversely to in humans [40, 125]. Finally, R58G mutation is described both in humans
and mice. This mutation does not seem to involve resistance in mice, and as the W59R mutation
in rat, it diminishes the VKOR activity [125]. Thus, the results obtained with VKORC1 enzyme
of rodents are in accordance with the in vitro results with human VKORC1 gene or VKORC1
enzyme.
The mutations at positions L128 and Y139 are the major mutations of the Norway rat. More‐
over, the studies on the Y139F mutations have shown that the resistance factor of this mutation
is conserved between in vivo and in vitro assays [55, 58]. In rats, these mutations involve
resistance factors against warfarin, which are of 8 for the L128Q mutation and greater than 200
for the Y139 mutations [58]. Moreover, in rats, L128Q does not seem to diminish the VKOR
activity while Y139F does it. Conversely, in humans, the L128R mutation conducts to a
reduction of more than 90% of the VKOR activity in enzymatic assay, with the VKORC1
enzyme produced in yeasts or HEK cells [32, 88]. But, this mutation does not modify the level
of gamma-carboxylation in cell assay [40, 84]. Possible origins of these discrepancies are argued
in Section 3.3. Consequently, it is currently difficult to conclude on the possible resistance
linked with the L128R mutation in humans.
As aforementioned, some mutations decrease the efficiency of the VKOR activity. Matagrin
has studied the origins of this loss of efficiency for the Y139 mutation [135]. He showed that
Y139 mutations involve a diminution of the VKOR activity and the creation of inactive vitamin
K metabolites (3-OH vitamin K) which are eliminated. This induces an increase of the food
requirements of vitamin K in rodents carrying these mutations [136, 137]. In humans, the
influence of coding mutations on nutritional requirement of vitamin K has not been well
studied [22]. However, by analogy with rodent mutations, human mutations might be
involved in cardiovascular diseases without VKA treatment [138]. Thus, the rodents carrying
these mutations might be use to model and to better understand the possible consequences of
these mutations on the human health.
4.2. Cytochrome-linked resistances
Cytochromes are essential elements in the elimination of xenobiotics. Thus, it would be
expected that their polymorphism might result in an origin of resistances. But in human
medicine, the cytochrome polymorphism is associated with an increase in the patient’s VKA
sensibility [93, 97]. Moreover, the polymorphism of CYP2C9 is a key element in the prediction
of the VKA treatment dose [97]. Thus, no VKA resistance linked to cytochrome has been
described in human medicine.
In rodents, expression profiles of cytochromes are different between sensitive and resistant
rats carrying a Y139C mutation on VKORC1 [139]. Nevertheless, it is difficult to identify the
part of the resistance due to VKORC1 mutation and the one due to the expression profiles of
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cytochromes. Nevertheless, one example of warfarin resistance linked to cytochrome has been
described without association with VKORC1 mutation in roof rats from Tokyo [140, 141]. This
rat population overexpresses the cytochrome 3A2. Thus, the concentration of blood warfar‐
in 1 h after the warfarin administration is eightfold lower in resistant rats. However, it is
currently the only reported case of cytochrome-linked resistance.
5. Conclusion
The assessment and the comprehension of the resistance mechanisms are essential in the safety
and the efficiency of VKA treatments and in the rodent population management. However,
the complexity of the mechanisms and the interactions between them prevent the use of only
one studying method. The understanding of the VKA actions and their interaction with
individual variability can only be achieved by a multiscale approach which combines humans,
rodents, and in vitro and in vivo knowledge.
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